Company Overview公司简介

Home / About Us关于我们 / Company Overview公司简介

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

Our technology includes 2 major cell platforms:

  • (i) Immune Cell therapy for treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (“CAR-T”) and anti-PD-1 Technologies

  • (ii) Human adipose-derived mesenchymal progenitor cells (“haMPC”) for treatment of joint and autoimmune diseases

Our primary research and manufacturing facilities are located in China. Our cellular platforms are based on technologies developed both in-house and obtained through acquisition, licensing and collaboration arrangements with other companies.


西比曼生物科技集团(纳斯达克: CBMG),致力于利用专有的细胞治疗技术为退行性疾病和癌症研发新的治疗方法。CBMG公司有近30年的人源间充质祖细胞、T细胞和肿瘤干细胞的技术研发和疾病治疗应用的经验,是一家领先的生物医药技术公司。我们所取得的细胞领域研发成就,是中美英3国的科学家和医生之间共同协作的结果。

  • (i)免疫肿瘤学: 嵌合抗原受体T细胞(CAR-T)疗法治疗肿瘤; 抗PD-1技术; CentrixT™自体T细胞免疫疗 

  • (ii)干细胞: 源于脂肪的成人间充质祖细胞(haMPC)